Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages

Journal of Clinical Investigation

Volumn 119, Issue 6, 2009, Pages 1524-1536

  Song, Liping ^a   Asgharzadeh, Shahab ^a   Salo, Jill ^a   Engell, Kelly ^a   Wu, Hong Wei ^a   Sposto, Richard ^a   Ara, Tasnim ^a   Silverman, Ayaka M ^a   DeClerck, Yves A ^a   Seeger, Robert C ^a,b   Metelitsa, Leonid S ^a,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S ONCOLOGY GROUP   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD1D ANTIGEN; CD68 ANTIGEN; INTERLEUKIN 6; CD1D PROTEIN, HUMAN; GLYCOLIPID; LYMPHOCYTE ANTIGEN RECEPTOR; VALPHA24 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; EVENT FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; MONOCYTE; MOUSE; NATURAL KILLER T CELL; NEUROBLASTOMA; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MACROPHAGE; METABOLISM; METASTASIS; PATHOLOGY;

ANIMALS; ANTIGENS, CD1D; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLIPIDS; HUMANS; INFANT; INTERLEUKIN-6; MACROPHAGES; MICE; NATURAL KILLER T-CELLS; NEOPLASM METASTASIS; NEUROBLASTOMA; RECEPTORS, ANTIGEN, T-CELL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66349083007     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI37869     Document Type: Article

References (71)

1. Kronenberg, M. 2005. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23:877-900.
2. Van Kaer, L., and Joyce, S. 2005. Innate immunity: NKT cells in the spotlight. Curr. Biol. 15:R429-R431.
3. Swann, J., Crowe, N.Y., Hayakawa, Y., Godfrey, D.I., and Smyth, M.J. 2004. Regulation of antitumour immunity by CD1d-restricted NKT cells. Immunol. Cell Biol. 82:323-331.
4. Gumperz, J.E. 2004. CD1d-restricted "NKT" cells and myeloid IL-12 production: an immunological crossroads leading to promotion or suppression of effective anti-tumor immune responses? J. Leukoc. Biol. 76:307-313.
5. Yanagisawa, K., et al. 2002. Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide. J. Immunol. 168:6494-6499.
6. Tahir, S.M., et al. 2001. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J. Immunol. 167:4046-4050.
7. Dhodapkar, M.V., et al. 2003. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med. 197:1667-1676.
8. Molling, J.W., et al. 2007. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J. Clin. Oncol. 25:862-868.
9. Metelitsa, L.S., et al. 2004. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J. Exp. Med. 199:1213-1221.
10. Brodeur, G.M., Seeger, R.C., Schwab, M., Varmus, H.E., and Bishop, J.M. 1984. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 224:1121-1124.
11. Tachibana, T., et al. 2005. Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin. Cancer Res. 11:7322-7327.
12. Brodeur, G.M. 2003. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer. 3:203-216.
13. Matthay, K.K., et al. 1999. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med. 341:1165-1173.
14. Seeger, R.C., et al. 1985. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med. 313:1111-1116.
15. Blackwood, E.M., and Eisenman, R.N. 1991. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science. 251:1211-1217.
16. Wanzel, M., Herold, S., and Eilers, M. 2003. Transcriptional repression by Myc. Trends Cell Biol. 13:146-150.
17. Song, L., et al. 2007. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. J. Clin. Invest. 117:2702-2712.
18. Metelitsa, L.S., et al. 2001. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J. Immunol. 167:3114-3122.
19. Smyth, M.J., et al. 2002. Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood. 99:1259-1266.
20. Eberl, G., and MacDonald, H.R. 2000. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur. J. Immunol. 30:985-992.
21. Baxevanis, C.N., Gritzapis, A.D., and Papamichail, M. 2003. In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18. J. Immunol. 171:2953-2959.
22. Introna, M., and Mantovani, A. 1983. Natural killer cells in human solid tumors. Cancer Metastasis Rev. 2:337-350.
23. Facchetti, P., et al. 1996. Functional and molecular characterization of tumour-infiltrating lymphocytes and clones thereof from a major- histocompatibility-complex-negative human tumour: neuroblastoma. Cancer Immunol. Immunother. 42:170-178.
24. Mantovani, A., Allavena, P., Sica, A., and Balkwill, F. 2008. Cancer-related inflammation. Nature. 454:436-444.
25. Sica, A., et al. 2008. Macrophage polarization in tumour progression. Semin. Cancer Biol. 18:349-355.
26. Sica, A., and Bronte, V. 2007. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117:1155-1166.
27. Spada, F.M., et al. 2000. Low expression level but potent antigen presenting function of CD1d on monocyte lineage cells. Eur. J. Immunol. 30:3468-3477.
28. Fukaya, Y., Shimada, H., Wang, L.C., Zandi, E., and DeClerck, Y.A. 2008. Identification of galectin-3-binding protein as a factor secreted by tumor cells that stimulates interleukin-6 expression in the bone marrow stroma. J. Biol. Chem. 283:18573-18581.
29. Sohara, Y., et al. 2005. Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells. Cancer Res. 65:1129-1135.
30. Liu, F.T., et al. 1995. Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages. Am. J. Pathol. 147:1016-1028.
31. Boltz-Nitulescu, G., et al. 1995. Modulation of IgA, IgE, and IgG Fc receptor expression on human mononuclear phagocytes by 1 alpha,25- dihydroxyvitamin D3 and cytokines. J. Leukoc. Biol. 58:256-262.
32. Kawanaka, N., et al. 2002. CD14+,CD16+ blood monocytes and joint inflammation in rheumatoid arthritis. Arthritis Rheum. 46:2578-2586.
33. Allavena, P., Sica, A., Solinas, G., Porta, C., and Mantovani, A. 2008. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol. 66:1-9.
34. Mantovani, A., Bottazzi, B., Colotta, F., Sozzani, S., and Ruco, L. 1992. The origin and function of tumor-associated macrophages. Immunol. Today. 13:265-270.
35. Papac, R.J. 1994. Bone marrow metastases. A review. Cancer. 74:2403-2413.
36. Metelitsa, L.S., Weinberg, K.I., Emanuel, P.D., and Seeger, R.C. 2003. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia. 17:1068-1077.
37. Hong, D.S., Angelo, L.S., and Kurzrock, R. 2007. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer. 110:1911-1928.
38. Brutkiewicz, R.R. 2006. CD1d ligands: the good, the bad, and the ugly. J. Immunol. 177:769-775.
39. Tsuji, M. 2006. Glycolipids and phospholipids as natural CD1d-binding NKT cell ligands. Cell. Mol. Life Sci. 63:1889-1898.
40. Platt, F.M., Neises, G.R., Karlsson, G.B., Dwek, R.A., and Butters, T.D. 1994. N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing. J. Biol. Chem. 269:27108-27114.
41. Paget, C., et al. 2007. Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids. Immunity. 27:597-609.
42. Fais, F., et al. 2005. CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis. Leukemia. 19:551-556.
43. Dhodapkar, K.M., et al. 2004. Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int. J. Cancer. 109:893-899.
44. Haraguchi, K., et al. 2006. CD1d expression level in tumor cells is an important determinant for antitumor immunity by natural killer T cells. Leuk. Lymphoma. 47:2218-2223.
45. Balkwill, F., and Mantovani, A. 2001. Inflammation and cancer: back to Virchow? Lancet. 357:539-545.
46. Gordon, S., and Taylor, P.R. 2005. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5:953-964.
47. Ara, T., et al. 2009. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res. 69:329-337.
48. Egler, R.A., Burlingame, S.M., Nuchtern, J.G., and Russell, H.V. 2008. Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma. Clin. Cancer Res. 14:7028-7034.
49. Mantovani, A., Schioppa, T., Porta, C., Allavena, P., and Sica, A. 2006. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 25:315-322.
50. Kreissman, S.G. 1993. Molecular genetics: toward an understanding of childhood cancer. Semin. Pediatr. Surg. 2:2-10.
51. Matsushima, K., Larsen, C.G., DuBois, G.C., and Oppenheim, J.J. 1989. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J. Exp. Med. 169:1485-1490.
52. Leek, R.D., et al. 2002. Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer. Cancer Res. 62:1326-1329.
53. Knowles, H., Leek, R., and Harris, A.L. 2004. Macrophage infiltration and angiogenesis in human malignancy. Novartis Found. Symp. 256:189-200.
54. Ceradini, D.J., et al. 2004. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10:858-864.
55. Kim, C.H., Johnston, B., and Butcher, E.C. 2002. Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among Valpha24(+)Vbeta11(+) NKT cell subsets with distinct cytokine-producing capacity. Blood. 100:11-16.
56. Chang, D.H., et al. 2005. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201:1503-1517.
57. Fujii, S., Liu, K., Smith, C., Bonito, A.J., and Steinman, R.M. 2004. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J. Exp. Med. 199:1607-1618.
58. Wu, D.Y., et al. 2003. Cross-presentation of disialoganglioside GD3 to natural killer T cells. J. Exp. Med. 198:173-181.
59. De Santo, C., et al. 2008. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J. Clin. Invest. 118:4036-4048.
60. Dunn, G.P., Old, L.J., and Schreiber, R.D. 2004. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 21:137-148.
61. Nieda, M., et al. 2004. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood. 103:383-389.
62. Motohashi, S., et al. 2006. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 12:6079-6086.
63. Uchida, T., et al. 2008. Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol. Immunother. 57:337-345.
64. + T cells. J. Clin. Invest. 116:2777-2790.
65. Gonzalez-Aseguinolaza, G., et al. 2002. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. 195:617-624.
66. Lu, X., Song, L., Metelitsa, L.S., and Bittman, R. 2006. Synthesis and evaluation of an alpha-C-galactosylceramide analogue that induces Th1-biased responses in human natural killer T cells. Chembiochem. 7:1750-1756.
67. Stirnemann, K., et al. 2008. Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice. J. Clin. Invest. 118:994-1005.
68. Matthay, K.K., et al. 1999. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med. 341:1165-1173.
69. Moss, T.J., et al. 1991. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N. Engl. J. Med. 324:219-226.
70. Reynolds, C.P., et al. 1988. Biological classification of cell lines derived from human extra-cranial neural tumors. Prog. Clin. Biol. Res. 271:291-306.
71. Metelitsa, L.S. 2004. Flow cytometry for natural killer T cells: multi-parameter methods for multifunctional cells. Clin. Immunol. 110:267-276.